Merck Serono's oral MS drug approved in Russia, its first market
This article was originally published in Scrip
Merck's Serono's oral relapsing-remitting multiple sclerosis (RRMS) drug Cladribine Tablets has been approved in the Russian Federation, its first market. It is expected to be made available in early 2011 under the trade name Movectro.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.